Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Twitter Formula Allows Tweets About Products Without Excessive Risks

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s draft guidance on presenting product information on social media platforms with character space limitations includes an equation for sending a tweet.

You may also be interested in...



Gottlieb's Tweets: Skirting The Rules Or Advancing Policy?

The current FDA commissioner discussed use of the social media platform with his predecessor Robert Califf at a meeting on real-world evidence.

Twitter Promo Study Gets Tweaks, But FDA Rejects Many Industry Suggestions

Lilly recommended testing use of embedded Twitter cards to convey safety information and PhRMA proposed studying a universal graphic symbol or FDA's logo.

Rx Mobile Devices Promos: Benefits Often More Prominent Than Risks

In an analysis of direct-to-consumer mobile promotions, FDA found that risks and benefits are not equally prominent and accessible in the communications and their landing pages.

Related Content

Topics

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel